With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2304-30-5,Tetrabutylphosphonium chloride,as a common compound, the synthetic route is as follows.
2. Preparation of 2-Chlorosulfonyl-7-fluoro-5-methoxy-[1,2,4]triazolo[1,5-c]pyrimidine A mixture of 5.0 g (13 mmol) of 2,2′-dithiobis-(7-fluoro-5-methoxy[1,2,4]triazolo[1,5-c]pyrimidine), 75 mL of dichloromethane, 25 mL of water, and 0.3 g (1.0 mmol) tetrabutylphosphonium chloride was cooled to 3 C. and 6.0 g (8.5 mmol) of chlorine gas was added with stirring and cooling. The mixture was allowed to react at 0 to 3 C. with stirring for 2 hours by which time the initial slurry had become clear leaving two liquid phases. The phases were separated and the organic phase was concentrated by evaporation under reduced pressure to obtain 7.5 g of the title compound in impure form as a white solid. 1 H NMR Spectrum (300 MHz) in CDCl3: 6.96(s, 1 H), 5.29(s, 1 H), 4.40(s, 3 H)., 2304-30-5
The synthetic route of 2304-30-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Dow AgroSciences LLC; US6162915; (2000); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI